Skip to main content

Precigen, Inc.

corporate_fare Company Profile

Precigen, Inc.

PGEN·NASDAQ·Life Sciences·CIK 0001356090

We are a commercial-stage biopharmaceutical company focused on developing precision medicines. We use our proprietary technology platforms to create product candidates for urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technology platforms support the construction of gene programs for efficacy, delivery through viral, non-viral, and microbe-based methods for lower costs, and gene expression control for safety. Our therapeutic platforms, including AdenoVerse immunotherapy and UltraCAR-T, allow us to control gene expression and modify biological molecules to treat underlying disease conditions. We have also developed UltraPorator, a proprietary electroporation device, for rapid and cost-effective manufacturing of UltraCAR-T therapies. In August 2025, the FDA fully approved our product, Papzimeos (zopapogene imadenovec-drba, PRGN-2012), for adults with recurrent respiratory papillomatosis (RRP). RRP is a rare disease caused by chronic human papillomavirus (HPV) 6 or HPV 11 infection. Papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen of HPV types 6 and 11 proteins, aiming to generate an immune response against these proteins in RRP patients. Our clinical pipeline includes PRGN-2009, based on our AdenoVerse immunotherapy platform, and PRGN-3005, PRGN-3006, and PRGN-3007, built on our UltraCAR-T platform.

Precigen, Inc. (NASDAQ:PGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for PGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PGEN spans 10-Q, 8-K, 4, SCHEDULE 13D/A.

Recent high-impact activity:

  • Precigen Posts $35.8M Q3 Profit as Papzimeos Revenue Hits $72.9M
  • PAPZIMEOS Revenue Jumps 37% to $72.9M; Precigen Turns Cash Flow Positive a Quarter Early
  • FDA Grants Platform Technology Designation to Precigen's AdenoVerse
  • Precigen Achieves First Profitable Quarter with Strong Papzimeos Sales
  • Precigen Posts First-Ever Profit on $53.1M PAPZIMEOS Revenue, Sees Cash Flow Break-Even by Year-End

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$9.68M
Net Income
-$250.64M
Diluted EPS
-$1.37
Op. Cash Flow
-$87.83M
Free Cash Flow
-$89.83M
Operating Income
-$110.51M
Cash & Equivalents
$30.23M
Total Debt
$93.17M
Debt / Equity
4.46×
Net Margin
-25.88×
Shares Outstanding
353.91M sh
Source: 10-K · filed 2026-03-25 · accession 0001356090-26-000009

Short Interest & Short Volume

8.56 days to cover

FINRA reported short interest of 44,908,434 shares in PGEN as of the October 30, 2026 settlement, a 3.2% decrease from the prior period — about 8.6 days to cover at its recent average daily volume. On November 20, 2026, 46.9% of PGEN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)44,908,434 shares as of October 30, 2026
Change vs prior period▼ 3.2%
Days to cover8.56 at avg daily volume of 5,245,464
Daily short volume (FINRA facilities)46.9% of 2,389,961 shares on November 20, 2026
5-day average short volume43.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for PGEN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-24.

Incentive Plan Amendment Approved · 7 Million Additional Shares Authorized

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$4.24 +0.61% today
52-week range · as of 2026-11-04 $3.04 – $8.98
Market cap
$1.51B
Volume
6.1M (0.9× avg)
3-mo avg 6.6M
Live data · 2026-11-22 10:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PGEN - Latest Insights

PGEN
Nov 04, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.99
Real-time Price: $4.24 info
Change: -$0.7515 (-15%) info
Market Cap: $1.509B info
PGEN
Nov 04, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
8
Price at Filing: $5.01
Real-time Price: $4.24 info
Change: -$0.7755 (-15%) info
Market Cap: $1.509B info
PGEN
Sep 21, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.93
Real-time Price: $4.24 info
Change: -$3.69 (-47%) info
Market Cap: $1.509B info
PGEN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.27
Real-time Price: $4.24 info
Change: -$3.03 (-42%) info
Market Cap: $1.509B info
PGEN
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.35
Real-time Price: $4.24 info
Change: -$3.11 (-42%) info
Market Cap: $1.509B info
PGEN
Aug 04, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $4.24 info
Change: -$3.01 (-42%) info
Market Cap: $1.509B info
PGEN
Jun 24, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.40
Real-time Price: $4.24 info
Change: -$1.16 (-22%) info
Market Cap: $1.509B info
PGEN
May 13, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $4.24 info
Change: +$0.0958 (+2%) info
Market Cap: $1.509B info
PGEN
May 13, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $4.24 info
Change: +$0.0958 (+2%) info
Market Cap: $1.509B info
PGEN
May 13, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $4.26
Real-time Price: $4.24 info
Change: -$0.0242 (-0.57%) info
Market Cap: $1.509B info
PGEN
Apr 07, 2026, 7:00 AM EDT
Source: Access Newswire
Importance Score:
9
Price at Filing: $4.10
Real-time Price: $4.24 info
Change: +$0.1358 (+3%) info
Market Cap: $1.509B info
PGEN
Mar 31, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $3.89
Real-time Price: $4.24 info
Change: +$0.3458 (+9%) info
Market Cap: $1.509B info
PGEN
Mar 31, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $3.86
Real-time Price: $4.24 info
Change: +$0.3758 (+10%) info
Market Cap: $1.509B info
PGEN
Mar 25, 2026, 4:54 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.67
Real-time Price: $4.24 info
Change: +$0.5658 (+15%) info
Market Cap: $1.509B info
PGEN
Mar 25, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $4.24 info
Change: +$0.9158 (+28%) info
Market Cap: $1.509B info
PGEN
Mar 25, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.67
Real-time Price: $4.24 info
Change: +$0.5658 (+15%) info
Market Cap: $1.509B info
PGEN
Mar 25, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.90
Real-time Price: $4.24 info
Change: +$1.34 (+46%) info
Market Cap: $1.509B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets